^
    over2years
    A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Dec 2021
    Enrollment open • Trial initiation date
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive • NTRK fusion
    |
    XZP-5955
    over3years
    A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=360, Not yet recruiting, Xuanzhu Biopharmaceutical Co., Ltd.
    New P1/2 trial
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive • NTRK fusion
    |
    XZP-5955